Cell Therapeutics Inc. ( NASDAQ: CTIC ) is a Seattle, Washington-based
biotechnology company, engaged in the development, acquisition and
commercialization of treatments for cancer. The company is focusing on building
a biopharmaceutical company with a diversified portfolio of oncology drugs. Cell
Therapeutics, recently, announced that it filed an appeal on FDA decision on New
Drug Application for pixantrone to treat relapsed/refractory aggressive
non-hodgkin's lymphoma. The penny stock of Cell Therapeutics has a 52-week
range of $0.12-$1.40. Year-to-date, the stock is down 67.82%. Discovery
Laboratories Inc. ( NASDAQ: DSCO ) is a Warrington, Pennsylvania-based
biotechnology company, engaged in the development of surfactant therapies to
treat respiratory disorders and diseases. Last week, Discovery announced that
NIH awarded it Fast Track SBOR grant to support development of aerosolized KL4
surfactant. The penny stock of Discovery Laboratories has a 52-week range of
$0.17-$0.84. Year-to-date, the stock is down 42.72%. StemCells Inc. ( NASDAQ:
STEM ) is a Palo Alto, California-based biotechnology company, engaged in the
research, development and commercialization of stem cell therapeutics and
related enabling technologies for academia and industry. Earlier this month,
StemCells received authorization to conduct the world's first ever neural stem
cell trial in spinal cord injury. The penny stock of StemCells has a 52-week
range of $0.75-$1.58. Year-to-date, the stock is down 10.34%. AEterna Zentaris
Inc. ( NASDAQ: AEZS ) is a Canada-based drug development company, specializing
in oncology and endocrine therapy. Last week, AEterna Zentaris announced that it
received agreement from FDA on SPA for Solorel® to complete registration study
for diagnosis of adult growth hormone deficiency. The penny stock of AEterna
Zentaris has a 52-week range of $0.78-$2.19. Year-to-date, it is up 113.15%.
BioSante Pharmaceuticals Inc. ( NASDAQ: BPAX ) is a Lincolnshire, Illinois-based
specialty pharmaceutical company. The company focuses on the development of
products for female sexual health, menopause, contraception and male
hypogonadism. On Monday, BioSante announced that it will raise $18 million in
registered direct offering. The penny stock of BioSante has a 52-week range of
$1.29-$2.50. Year-to-date, the stock is up 14.48%. This corporate profile is
provided for information purposes only and should not be used as the basis for
any investment decision. We are neither licensed nor qualified to provide
investment advice. We were not paid, nor do we hold a position in these stocks.
We reserve the right to buy or sell CTIC, DSCO, STEM, AEZS and BPAX at any time
after this post.
No comments:
Post a Comment